Background. Hereditary primary hyperparathyroidism may be syndromic or nonsyndromic (familial isolated hyperparathyroidism). Recently, germline activating mutations in the GCM2 gene were identified in a subset of familial isolated hyperparathyroidism. This study examined the clinical and biochemical characteristics and the treatment outcomes of GCM2 mutation-positive familial isolated hyperparathyroidism as compared to sporadic primary hyperparathyroidism. Methods. We performed a retrospective analysis of clinical features, parathyroid pathology, and operative outcomes in 18 patients with GCM2 germline mutations and 457 patients with sporadic primary hyperparathyroidism.
Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia and is a relatively common endocrine disorder with an estimated prevalence of 1 to 7 cases per 1,000 persons. [1] [2] [3] The incidence peaks in the seventh decade of life, and it is more common in postmenopausal women, with a prevalence of ≤3.2%. 4 PHPT is due to a parathyroid neoplasm(s), which hypersecretes parathyroid hormone (PTH). PHPT may be sporadic or inherited. Inherited PHPT may be syndromic, such as in multiple endocrine neoplasia types 1, 2, and 4 (MEN1, 2, 4) and the hyperparathyroidism jaw-tumor syndrome (HPT-JT), or it may be nonsyndromic, which is also referred to as familial, isolated primary hyperparathyroidism (FIHP). 5 Approximately 10% of PHPT is hereditary. Patients with syndromic PHPT usually present at a younger age, are more likely to have multigland disease, and have lesser rates of cure of the hyperparathyroidism, greater rates of recurrent PHPT, and greater risk of parathyroid carcinoma, such as in HPT-JT as compared with sporadic PHPT. [5] [6] [7] [8] [9] [10] Genetic studies have identified several susceptibility genes responsible for syndromic PHPT. MEN1 is the most common familial form of PHPT, with 2% to 4% of PHPT patients carrying a germline mutation in the tumor suppressor gene, MEN1, located on chromosome 11q13. Almost all MEN1 patients will develop PHPT by the age of 50 and are more likely to have multigland disease. MEN2 is due to a germline mutation in the RET proto-oncogene. Nearly all patients with MEN2 develop medullary thyroid carcinoma by the third decade of life, with patients with MEN2 being at risk of pheochromocytomas (50% penetrance) and PHPT (20% penetrance). There is a genotype-phenotype association in MEN2, with a mutation in codon 634 being associated most commonly with PHPT. 3 HPT-JT is a rare, autosomal-dominant disorder due to a germline mutation in CDC73 and has an incomplete penetrance and variable expression. 6 PHPT occurs in ≈90% of carriers, and ossifying fibromas of the Contents lists available at ScienceDirect Surgery j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y m s y mandible and/or maxilla occur in 35% of patients. 5 HPT-JT is more aggressive with frequent multigland involvement, increased risk of persistent/recurrent disease, and a greater frequency of parathyroid carcinoma in ≤38% of patients. 6 FIHP is an autosomal-dominant disorder characterized by the absence of a nonparathyroid clinical manifestation of known syndromic PHPT. Some patients with FIHP may represent variants of other syndromic PHPT with incomplete penetrance because germline mutations in MEN1, CDC73, and CASR genes have been reported in some patients with FIHP. 11, 12 Recently, Guan et al identified GCM2 germline activation mutations in 7 of 40 (18%) kindreds with FIHP. 13 Thus, activating germline mutations in GCM2 could be one of the more common causes of FIHP and nonsyndromic PHPT.
The aim of our study was to evaluate the clinical, biochemical, and pathologic characteristics as well as outcomes after parathyroidectomy in GCM2-associated PHPT as compared to patients with sporadic PHPT.
Patients and Methods
Patients were enrolled into clinical protocols after providing written informed consent. These protocols were approved by the Institutional Review Boards of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute.
Patients with no family history of PHPT based on a family history questionnaire were considered to have sporadic PHPT (n = 457). Patients with PHPT were diagnosed with FIHP (n = 18) when they had first degree relative(s) with PHPT in the absence of sufficient clinical, radiologic, or biochemical evidence for diagnoses of MEN1, MEN2, HPT-JT, or familial hypocalciuric hypercalcemia. Index cases from FIHP kindreds had negative genetic testing results for germline mutations in MEN1, CDC73, or CASR and for duplication and deletions in MEN1 and CDC73; these genomic evaluations were performed in a clinical laboratory improvement amendmentscertified laboratory. The GCM2 mutations were identified previously by whole-exome sequencing and Sanger sequencing. 13 Baseline demographic and biochemical characteristics, including age, sex, serum calcium and intact PTH levels, and type and extent of operative intervention and postoperative data were evaluated and compared between patients with GCM2-associated FIHP and sporadic PHPT. Biochemical cure was defined as the presence of documented normal serum calcium levels for at least 2 years of postoperative follow-up.
Statistical analysis
Dichotomous data were analyzed using the χ 2 test, and continuous variables were analyzed using a 2-sample t test. Data are presented as mean (±standard deviation) or median (range). For nonparametric, continuous variables, the Kruskal-Wallis test was used to determine statistical significance between variables. If found to be statistically significant, a Mann-Whitney U test then was used for 2-group comparison. All P values reported are 2-tailed.
Results
Eighteen patients (12 females and 6 males) had a germline GCM2-activating mutation and were diagnosed with PHPT at 17 to 79 years of age. Summarized in Table I are the baseline demographics of GCM2 mutation carriers and patients with sporadic PHPT. There was a similar sex distribution (female: 67% vs 78.4%; P = .31), age at diagnosis (54 ± 16 vs 59.2 ± 13.5 years; P = .105), and race/ethnicity (P = .363) between GCM2 mutation carriers and patients with sporadic PHPT (Table I ). The serum calcium levels were similar between GCM2 mutation carriers and patients with sporadic PHPT, respectively (Ca: 2.85 ± 0.29 vs 2.76 ± 0.32; P = .183), while the preoperative serum intact PTH level was greater in GCM2 mutation carriers compared with patients with sporadic PHPT (239 ± 394 vs 136 ± 113, respectively, P = .005).
All GCM2 mutation carrier patients underwent initial, bilateral neck exploration; this rate of bilateral exploration was significantly greater compared with patients with sporadic PHPT. The multigland disease rate was much greater in GCM2 mutation carriers compared with patients with sporadic PHPT (78% vs 14.3%, P < .001; Table II ). One patient in the GCM2 mutation carrier group had a parathyroid carcinoma (5% vs 0%, P = .04; Table II ). The GCM2 variant mutation had a lesser biochemical cure rate after parathyroidectomy compared with the sporadic group (87%; vs 99.1%, P < .001). When we evaluated the operative outcomes of patients with GCM2-associated PHPT based on whether or not they were the index case, we found nonindex cases (i.e., those family members screened for PHPT) had a greater rate of biochemical cure and required less reoperative interventions (Fig) .
Discussion
FIHP typically has an autosomal-dominant pattern of inheritance. Recently, 2 different germline, GCM2-activating mutations were discovered in a subset of kindreds with FIHP and may account for a substantial fraction of FIHP. 13 The diagnosis of FIHP is based on a diagnosis of exclusion and requires the presence of at least 2 firstdegree relatives with PHPT and no evidence of other nonparathyroid clinical features of syndromic PHPT (MEN1, MEN2, and HPT-JT). These criteria, however, may not exclude the chance occurrence of 2, firstdegree relatives having nonhereditary PHPT, given that PHPT is common in the general population. Thus, the presence of activating germline mutations in the GCM2 could have important clinical ramifications in kindreds with FIHP in regard to screening, surveillance, and treatment. Thus, to determine the clinical characteristics of GCM2-associated FIHP that may influence the management of PHPT, we compared GCM2-activation mutation carriers with patients with sporadic PHPT. We found a significantly greater rate of multigland disease and a case of parathyroid carcinoma on pathology as well as a lesser rate of biochemical cure in the GCM2 group. The onset of hypercalcemia in syndromic PHPT patients occurs most commonly in the second and third decades of life. PHPT in patients with MEN1 is the earliest and most common manifestation, occurring in 90% of patients between 20 and 25 years of age.
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In MEN2, PHPT usually presents at an average age of 38 years. [14] [15] [16] HPT-JT is diagnosed at a median age of 27 to 31 years of age. 6 Compared with the sporadic PHPT in our study cohort, GCM2-associated FIHP patients had a similar age at diagnosis (54 years), with the earliest age at onset being 17 years. The early age of diagnosis in syndromic PHPT also could be due to prospective screening for hypercalcemia once a family member has been identified. In kindreds with GCM2-associated FIHP, screening should be considered starting at 17 years of age in GCM2 variant carriers.
Contrary to our expectation of having an even sex distribution in patients with GCM2-associated PHPT, we found a predominance of females affected (12 of 18), which is similar to the sex distribution of sporadic PHPT. The small number of patients with GCM2-associated PHPT, along with the fact that some family members may not have been investigated yet or may have died before PHPT symptoms developed or PHPT was diagnosed, may explain the sex distribution in our study cohort. Future screening and surveillance studies of all at-risk family members is needed to ascertain whether there is a sex difference in GCM2-associated PHPT manifestation.
One of the cardinal features of inherited syndromic and nonsyndromic endocrine neoplasm is the presence of multiplicity of tumors. Indeed, we observed a rate of multigland disease in GCM2-associated PHPT that was significantly greater than sporadic cases of PHPT. Furthermore, one patient had parathyroid carcinoma, which is rare in sporadic PHPT but common in HPT-JT. 6, 17 These findings have important implications for management of patients, suggesting that patients with GCM2-associated PHPT may require routine, bilateral neck exploration and identification of all parathyroid glands to prevent failure of parathyroidectomy by overlooking the presence of multigland disease. Knowledge that these patients are at risk of parathyroid carcinoma could allow a more cognizant consideration of the possibility of a parathyroid carcinoma intraoperatively and closer long-term follow-up. 6, 9 Patients with GCM2-associated PHPT had a significantly lesser rate of biochemical cure and required multiple reoperations. This lesser cure rate is similar to that observed in other inherited PHPT, such as MEN1 and HPT-JT, during long-term follow-up. 6, 9, 18 The high recurrence rate might be explained by the observation that GCM2 is a transcription factor expressed specifically in the parathyroid glands and is critical in the development of parathyroid glands. 19 The 7 cases of recurrent/persistent PHPT in carriers of germline GCM2-activation mutations highlights the lesser rate of biochemical cure in this disorder; 16 operative interventions were required, with many of these patients having multiple reoperations. This observation is important, because reoperations are associated with an increased risk of complications. Thus, preoperative knowledge of the carrier status in patients with FIHP who have a germline, GCM2-activating mutation should be performed before the initial operation to not only provide the best chance for definitive treatment but also to minimize the need for reoperation and its associated morbidity.
The present study has several limitations. Although patients with sporadic PHPT had no family history of PHPT and not all had genetic testing, some cases may be de novo cases of inherited PHPT. We, however, think this would represent a very low number of cases. The greater rate of parathyroid carcinoma in GCM2 mutationpositive kindreds we report also is based on only 1 of 18 patients (Table II) and in a patient who lacked documented distant metastases. 17 Thus, more study and surveillance of GCM2 mutationpositive kindreds will be necessary to confirm this association. The retrospective study design does not allow us to ascertain disease characteristic completely as well as some data elements, such as metabolic complications associated with PHPT, the rationale for the initial surgical decision-making, and the accuracy of preoperative localizing studies in GCM2-associated PHPT to help distinguish between single and multigland disease.
In summary, patients with FIHP due to germline GCM2-activating mutation have greater preoperative serum PTH levels, a greater rate of multigland disease, a lesser rate of biochemical cure, and an apparent increased risk of parathyroid carcinoma. Knowledge of these clinical characteristics along with preoperative knowledge of the GCM2-activating mutation status could lead to more optimal surgical management of GCM2 mutation-associated FIHP. 
Discussion
Dr Sareh Parangi (Boston, MA): So how do you choose who to do this genetic test on from a practical standpoint? Like, I see a patient and they say they have one family member, maybe it was a sister, maybe they were exposed to some radiation as a child. How do I decide who to run this mutation test on?
Dr Mustapha El Lakis: That is an excellent question, by the way. So, we are looking currently in a different study to answer this question. However, the current recommendation from the AAES and from the European Association of Endocrine Surgeons recommend genetic testing for patients <45 years of age or <40 years of age. It depends on which recommendation and patients who have persistent or recurrent primary hyperparathyroidism.
From the technical point of view, this GCM2 mutation, there is a panel currently being elaborated. It is not yet published, that is as far as I know, for the GCM2 mutation.
Dr Sareh Parangi (Boston, MA): Is there any immunohistochemical antibody test that could be done for the mutation?
Dr Mustapha El Lakis: I am not aware of that. Dr Quan Yang (San Francisco, CA): A very interesting study. A quick question. Do these multiglandular disease patients look more like MEN1 patients or look more like the usual isolated, familial isolated, just one gland? And in relationship to that is your preoperative localizing study. Do you see any differences?
Dr Mustapha El Lakis: So that is also an excellent question. We did not have access to the database, and we were not able to, since it is a retrospective study. Not all patients had consistent preoperative localizing studies, so we were not able to look at this point. But we were trying to do so. Unfortunately, it was a retrospective analysis.
Dr John A. Olson (Baltimore, MD): Really great work. That is very cool. I am trying to think, your explanation of how the GCM activating mutation leads to elevated parathyroid hormone. It is easy to understand when you think about it sitting on a promotor, making more PTH and releasing more hormone. But can you speculate how that actually leads to a tumor? Dr Mustapha El Lakis: Technically, the GCM2 is a transcription factor that is involved in the development of the parathyroid gland.
In animal knockout models, when they took out GCM2, the parathyroid gland did not develop.
So, the presence of this gene is essential for the development of the gland. In this specific mutation, the variants that were detected, there was association with familial primary hyperparathyroidism and persistence of the disease.
As we can see, there is multigland disease and recurrence of the disease, so that might explain that there is a germline mutation that keeps on resulting in probably hyperplasia or other abnormality of the other gland that we are not taking out from the first surgery.
Dr Matthew A. Nehs (Boston, MA): And to that exact point, what operation should you do for single gland disease? So you showed several patients who had single gland disease. Do you still then do a subtotal, leaving half a gland of the most normal, or do you just do surveillance? Dr Mustapha El Lakis: To answer this question, we have to relate it to the risk of cancer. The risk of cancer was low. One patient was detected in the whole series of 18 patients. I would say we would just take out the abnormal glands and keep an active surveillance for the other glands. 
